ESR2 and breast carcinoma: METTL17 can act as a coactivator of ERs, and inhibition of METTL17 leads to reduced transcriptional activity of ERα and ERβ in breast cancer cells, reduces the expression of ER target genes and limits the growth of breast cancer cells.57